 "Chopra is a Cipla veteran and has been with the company for nearly two and a half decades")
Drugmaker Cipla has seen three senior-level exits as it navigates Covid-19 challenges in the country and ramps up focus on chronic therapies. Those leaving the company include Nikhil Chopra, head of India business, Nikhil Lalwani, who served as head of US business, and Kunal Khanna, head of chronic and emerging therapies.
Chopra is a Cipla veteran and has been with the company for nearly two and a half decades. Lalwani was to move to India as a head of prescriptions but could not join because of travel restrictions, it is learnt. He has now joined another drugmaker in the US
